These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related]
3. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice. Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A mBio; 2021 Apr; 12(2):. PubMed ID: 33879586 [TBL] [Abstract][Full Text] [Related]
4. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. Yinda CK; Port JR; Bushmaker T; Offei Owusu I; Purushotham JN; Avanzato VA; Fischer RJ; Schulz JE; Holbrook MG; Hebner MJ; Rosenke R; Thomas T; Marzi A; Best SM; de Wit E; Shaia C; van Doremalen N; Munster VJ PLoS Pathog; 2021 Jan; 17(1):e1009195. PubMed ID: 33465158 [TBL] [Abstract][Full Text] [Related]
5. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. Golden JW; Zeng X; Cline CR; Garrison AR; White LE; Fitzpatrick CJ; Kwilas SA; Bowling PA; Fiallos JO; Moore JL; Sifford WB; Ricks KM; Mucker EM; Smith JM; Hooper JW J Gen Virol; 2021 May; 102(5):. PubMed ID: 33961540 [TBL] [Abstract][Full Text] [Related]
6. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development. Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780 [TBL] [Abstract][Full Text] [Related]
8. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. Golden JW; Li R; Cline CR; Zeng X; Mucker EM; Fuentes-Lao AJ; Spik KW; Williams JA; Twenhafel N; Davis N; Moore JL; Stevens S; Blue E; Garrison AR; Larson DD; Stewart R; Kunzler M; Liu Y; Wang Z; Hooper JW mBio; 2022 Feb; 13(1):e0290621. PubMed ID: 35073750 [TBL] [Abstract][Full Text] [Related]
9. Development of transgenic models susceptible and resistant to SARS-CoV-2 infection in FVB background mice. Seo SM; Son JH; Lee JH; Kim NW; Yoo ES; Kang AR; Jang JY; On DI; Noh HA; Yun JW; Park JW; Choi KS; Lee HY; Shin JS; Seo JY; Nam KT; Lee H; Seong JK; Choi YK PLoS One; 2022; 17(7):e0272019. PubMed ID: 35881617 [TBL] [Abstract][Full Text] [Related]
11. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Fumagalli V; Ravà M; Marotta D; Di Lucia P; Laura C; Sala E; Grillo M; Bono E; Giustini L; Perucchini C; Mainetti M; Sessa A; Garcia-Manteiga JM; Donnici L; Manganaro L; Delbue S; Broccoli V; De Francesco R; D'Adamo P; Kuka M; Guidotti LG; Iannacone M Sci Immunol; 2022 Jan; 7(67):eabl9929. PubMed ID: 34812647 [TBL] [Abstract][Full Text] [Related]
12. Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. Kim SH; Kim J; Jang JY; Noh H; Park J; Jeong H; Jeon D; Uhm C; Oh H; Cho K; Jeon Y; On D; Yoon S; Lim SY; Kim SP; Lee YW; Jang HJ; Park IH; Oh J; Seo JS; Kim JJ; Seok SH; Lee YJ; Hong SM; An SH; Kim SY; Kim YB; Hwang JY; Lee HJ; Kim HB; Choi KS; Park JW; Seo JY; Yun JW; Shin JS; Lee HY; Kim K; Lee D; Lee H; Nam KT; Seong JK Front Immunol; 2022; 13():1055811. PubMed ID: 36457995 [TBL] [Abstract][Full Text] [Related]
13. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. Kumari P; Rothan HA; Natekar JP; Stone S; Pathak H; Strate PG; Arora K; Brinton MA; Kumar M Viruses; 2021 Jan; 13(1):. PubMed ID: 33477869 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Cáceres CJ; Cardenas-Garcia S; Carnaccini S; Seibert B; Rajao DS; Wang J; Perez DR Sci Rep; 2021 May; 11(1):9609. PubMed ID: 33953295 [TBL] [Abstract][Full Text] [Related]
15. Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice. Olivarria GM; Cheng Y; Furman S; Pachow C; Hohsfield LA; Smith-Geater C; Miramontes R; Wu J; Burns MS; Tsourmas KI; Stocksdale J; Manlapaz C; Yong WH; Teijaro J; Edwards R; Green KN; Thompson LM; Lane TE J Virol; 2022 Feb; 96(4):e0196921. PubMed ID: 34935438 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Winkler ES; Bailey AL; Kafai NM; Nair S; McCune BT; Yu J; Fox JM; Chen RE; Earnest JT; Keeler SP; Ritter JH; Kang LI; Dort S; Robichaud A; Head R; Holtzman MJ; Diamond MS Nat Immunol; 2020 Nov; 21(11):1327-1335. PubMed ID: 32839612 [TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
20. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice. He Y; Henley J; Sell P; Comai L Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]